Hôpital Cardiologique du Haut Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux-Pessac, France.
L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Bordeaux-Pessac, France.
J Cardiovasc Electrophysiol. 2021 Nov;32(11):2987-2994. doi: 10.1111/jce.15231. Epub 2021 Sep 1.
Ventricular fibrillation (VF) is the main mechanism of sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). The origin of VF and the success of catheter ablation to eliminate recurrent episodes in this population are poorly understood.
From 2010 to 2014, five patients with HCM (age 21 ± 9 years, three female) underwent invasive electrophysiological studies and ablation at our center after resuscitation from recurrent (9 ± 7) episodes of VF. Ventricular premature beats (VPBs), seen to initiate VF in certain cases, were recorded noninvasively before the ablation procedure. Postprocedural computed tomography (CT) was performed to correlate ablation sites with myocardial hypertrophy in three patients. Outcomes were assessed by clinical follow-up and implantable cardioverter-defibrillator interrogations. VPB triggers were localized invasively to the distal left Purkinje conduction system (left posterior fascicle [2], left anterior fascicle [1], and both fascicles [2]). All targeted VF triggers were successfully eliminated by radiofrequency ablation in the left ventricle. Among patients with postablation CT imaging, 93 ± 12% of ablation sites corresponded to hypertrophied segments. Over 50 ± 38 months, four of five patients were free from primary VF without antiarrhythmic drug therapy. One patient who had 13 episodes of VF before ablation had a single recurrence.
In our study of patients with HCM and recurrent VF, VF was not initiated from the myocardium but rather from Purkinje arborization. These sources colocalized with the hypertrophic substrate, suggesting electromechanical interaction. Focal ablation at these sites was associated with a marked reduction in VF burden.
心室颤动(VF)是肥厚型心肌病(HCM)患者心源性猝死的主要机制。VF 的起源以及导管消融在该人群中消除复发性发作的成功率尚不清楚。
2010 年至 2014 年,我院对 5 例 HCM 患者(年龄 21±9 岁,3 例女性)进行了侵入性电生理研究和消融治疗,这些患者在复发性(9±7)VF 发作后接受了治疗。在消融前的程序中,记录到了在某些情况下会引发 VF 的室性早搏(VPB)。对 3 例患者进行了消融后 CT 检查,以确定消融部位与心肌肥厚的相关性。通过临床随访和植入式除颤器检查来评估结果。VPB 触发部位通过侵入性手段定位于左浦肯野纤维系统的远端(左后束[2]、左前束[1]和两个束[2])。所有靶向 VF 触发均通过左心室射频消融成功消除。在进行消融后 CT 成像的患者中,93±12%的消融部位与肥厚的节段相对应。在 50±38 个月的随访期间,5 例患者中有 4 例在没有抗心律失常药物治疗的情况下免于原发性 VF。1 例患者在消融前有 13 次 VF 发作,仅复发了 1 次。
在我们对 HCM 伴复发性 VF 的患者的研究中,VF 并非起源于心肌,而是起源于浦肯野树突。这些起源部位与肥厚的基质重合,提示电机械相互作用。这些部位的焦点消融与 VF 负荷的显著降低相关。